Answers are grounded in this paper and cite their sources.
Introduction The burden of atherosclerotic cardiovascular disease (ASCVD) persists globally, demanding innovative therapeutic strategies. This manuscript provides an expert opinion on the significance of managing low-density lipoprotein cholesterol in ASCVD prevention and introduces inclisiran, a novel small interfering RNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
No takes yet. Share an insight, caveat, or question.
Barkas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: